Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 1
1970 1
1975 2
1976 1
1985 1
1988 1
1991 2
1994 1
1995 2
1996 1
1997 4
1998 2
1999 7
2000 4
2001 4
2002 3
2003 7
2004 6
2005 7
2006 6
2007 8
2008 7
2009 7
2010 5
2011 2
2012 6
2013 12
2014 17
2015 8
2016 11
2017 9
2018 6
2019 5
2020 10
2021 8
2022 5
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: hodge jw. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: hodge jw. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.
Therapeutic cancer vaccines.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Schlom J, et al. Among authors: hodge jw. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Adv Cancer Res. 2014. PMID: 24889529 Free PMC article. Review.
Rationale for IL-15 superagonists in cancer immunotherapy.
Knudson KM, Hodge JW, Schlom J, Gameiro SR. Knudson KM, et al. Among authors: hodge jw. Expert Opin Biol Ther. 2020 Jul;20(7):705-709. doi: 10.1080/14712598.2020.1738379. Epub 2020 Mar 11. Expert Opin Biol Ther. 2020. PMID: 32159390 No abstract available.
Natural Born Killers: NK Cells in Cancer Therapy.
Franks SE, Wolfson B, Hodge JW. Franks SE, et al. Among authors: hodge jw. Cancers (Basel). 2020 Jul 31;12(8):2131. doi: 10.3390/cancers12082131. Cancers (Basel). 2020. PMID: 32751977 Free PMC article. Review.
Enhancing immune responses to tumor-associated antigens.
Higgins JP, Bernstein MB, Hodge JW. Higgins JP, et al. Among authors: hodge jw. Cancer Biol Ther. 2009 Aug;8(15):1440-9. doi: 10.4161/cbt.8.15.9133. Epub 2009 Aug 1. Cancer Biol Ther. 2009. PMID: 19556848 Free PMC article. Review.
181 results